What is the study asking?
Evaluating clemastine as a potential remyelinating agent after acute optic neuritis. This is a randomized, double-blind, placebo-controlled study.
Clemastine is being investigated for myelin repair in this study; it is not approved for this use.
Participation at a glance
- Approximate duration
- 9 months
- Minimum visits
- 5 at UCSF
- Typical visit
- 3 hours
Study visit sequence
- Screening
- Week 1
- Month 1
- Month 3
- Month 9
The original lab overview describes random assignment to three months of clemastine or placebo, followed by evaluation at month nine.
Who may be eligible?
The official listing includes adults ages 18–55 with diagnosed or suspected acute demyelinating optic neuritis within three weeks of the onset of visual symptoms other than pain. Additional inclusion and exclusion criteria apply.
Read full criteria on UCSF Clinical Trials
The study team determines eligibility and explains the current protocol, potential risks, and consent process. This overview is not treatment advice.
Ask the study team
Use the official UCSF study page to check availability and contact the team.